Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date

Advances in therapies have led to the approval of six therapeutic agents since 2004, each demonstrating overall survival benefit in randomized studies, and these have significantly improved the outlook for men facing metastatic castration-resistant prostate cancer (CRPC). More recently, efforts have...

Descripción completa

Detalles Bibliográficos
Autores principales: Chong, Julio T, Oh, William K, Liaw, Bobby C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905496/
https://www.ncbi.nlm.nih.gov/pubmed/29695920
http://dx.doi.org/10.2147/OTT.S147168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905496/
https://www.ncbi.nlm.nih.gov/pubmed/29695920
http://dx.doi.org/10.2147/OTT.S147168

Ejemplares similares